Resverlogix Corp. · TSX:RVX

Resverlogix — Technical Presentation (2021)

6 slides from Resverlogix's technical presentation, 2021

  1. Slide 1: Apabetalone, a Clinical-stage Cardiovascular Disease Drug, Inhibits DUX4 Expression in FSHD Cells

    TSX: RVX Apabetalone, a Clinical-stage Cardiovascular Disease Drug, Inhibits DUX4 Expression in FSHD Cells Christopher D. Sarsons1, Dean Gilham1, Laura M. Tsujikawa1, Li Fu1, Sylwia Wasiak1, Brooke D. Rakai1, Stephanie C. Stotz1, Michael Sweeney2, Jan O. Johansson2, Norman C. Wong1, Ewelina Kulikows

  2. Slide 2: Introduction

    Introduction • Apabetalone is a clinical stage BET inhibitor for cardiovascular disease – With a demonstrated clinical safety profile • Apabetalone inhibits DUX4 transcription through an epigenetic mechanism • Here we show apabetalone reverses DUX4- mediated gene expression – Without significantly i

  3. Slide 3: Apabetalone Inhibits FSHD Disease Markers in Primary Myotubes

    Apabetalone Inhibits FSHD Disease Makers in Primary Myotubes Apabetalone treatment effectively inhibits FSHD disease markers (A), without significantly affecting markers of muscle cell differentiation (B) A B 3

  4. Slide 4: Apabetalone Counters DUX4 Activation During Differentiation

    Apabetalone Counters DUX4 Activation During Differentiation DUX4 activation during differentiation (3 day) increased expression of known DUX4 targets (A). Apabetalone treatment (5µM for 24h) significantly reduced expression of nearly all DUX4 targets in differentiated myotubes (B) A B SLC34A2 SLC34A

  5. Slide 5: Reduces DUX4 Signature and Rescues PAX7 Activity

    Apabetalone Reduces DUX4 Signature and Rescues PAX7 Activity Apabetalone treatment (5µM for 24h) lowers the mean expression of DUX4 signature genes (A) and partially rescues PAX7 activity (B), which is a critical signal of muscle cell function A Geng et al. Yao et al. Choi et al. B 15 Banerji et al.

  6. Slide 6: Conclusions

    Conclusions • Misexpression of DUX4 drives pathogenesis in FSHD • Apabetalone inhibits the expression of DUX4 in FSHD muscle cells • Mean expression of DUX4 target genes was significantly reduced with apabetalone treatment • PAX7 activity, as well as CNTF and ERK/MAPK signaling, all important for mu

Resverlogix — Technical Presentation (2021) on 6ix